{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T19:40:01Z","timestamp":1770579601322,"version":"3.49.0"},"reference-count":41,"publisher":"Japan Endocrine Society","issue":"2","funder":[{"name":"Beijing Institute of Hepatology Reform and Development Project","award":["2024Y-KF-10"],"award-info":[{"award-number":["2024Y-KF-10"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0123","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T22:06:53Z","timestamp":1761689213000},"page":"193-203","source":"Crossref","is-referenced-by-count":0,"title":["Association of physical activity and sedentary time with risk of non-alcoholic fatty liver disease in adults with and without diabetes mellitus"],"prefix":"10.1507","volume":"73","author":[{"given":"Yulin","family":"Zheng","sequence":"first","affiliation":[{"name":"Beijing Institute of Hepatology, Department of Critical Medicine, Beijing YouAn Hospital, Capital Medical University, Beijing, 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Hepatology, Department of Critical Medicine, Beijing YouAn Hospital, Capital Medical University, Beijing, 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Hepatology, Department of Nursing, Beijing YouAn Hospital, Capital Medical University, Beijing, 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Emergency, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1638-3922","authenticated-orcid":false,"given":"Yanmei","family":"Gu","sequence":"additional","affiliation":[{"name":"Beijing Institute of Hepatology, Department of Critical Medicine, Beijing YouAn Hospital, Capital Medical University, Beijing, 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5043-2895","authenticated-orcid":false,"given":"Linjing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Emergency, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Leung PB, Davis AM, Kumar S (2023) Diagnosis and management of nonalcoholic fatty liver disease. JAMA 330: 1687\u20131688.","DOI":"10.1001\/jama.2023.17935"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Le MH, Le DM, Baez TC, Wu Y, Ito T, et al. (2023) Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol 79: 287\u2013295.","DOI":"10.1016\/j.jhep.2023.03.040"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Wong VW, Ekstedt M, Wong GL, Hagstr\u00f6m H (2023) Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol 79: 842\u2013852.","DOI":"10.1016\/j.jhep.2023.04.036"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Younossi ZM, AlQahtani SA, Funuyet-Salas J, Romero-G\u00f3mez M, Yilmaz Y, et al. (2024) The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Rep 6: 101066.","DOI":"10.1016\/j.jhepr.2024.101066"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Pierantonelli I, Svegliati-Baroni G (2019) Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression From NAFLD to NASH. Transplantation 103: e1\u2013e13.","DOI":"10.1097\/TP.0000000000002480"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Svegliati-Baroni G, Pierantonelli I, Torquato P, Marinelli R, Ferreri C, et al. (2019) Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. Free Radic Biol Med 144: 293\u2013309.","DOI":"10.1016\/j.freeradbiomed.2019.05.029"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, et al. (2016) Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 31: 936\u2013944.","DOI":"10.1111\/jgh.13264"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Liu Z, Zhang Y, Graham S, Wang X, Cai D, et al. (2020) Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol 73: 263\u2013276.","DOI":"10.1016\/j.jhep.2020.03.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, et al. (2024) The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol 22: 1999\u20132010.e1998.","DOI":"10.1016\/j.cgh.2024.03.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Stefan N, Cusi K (2022) A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 10: 284\u2013296.","DOI":"10.1016\/S2213-8587(22)00003-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Cao L, An Y, Liu H, Jiang J, Liu W, et al. (2024) Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis. BMC Med 22: 101.","DOI":"10.1186\/s12916-024-03315-0"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12 En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, et al. (2023) Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut 72: 2138\u20132148.","DOI":"10.1136\/gutjnl-2023-330110"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Dehghani Firouzabadi M, Poopak A, Sheikhy A, Dehghani Firouzabadi F, Moosaie F, et al. (2024) Nonalcoholic fatty liver disease as a potential risk factor for cardiovascular disease in patients with type 2 diabetes: a prospective cohort study. Int J Endocrinol 2024: 5328965.","DOI":"10.1155\/2024\/5328965"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Marchesini G BE, Burra P, Marra F, Miele L, et al. (2022) Non-alcoholic fatty liver disease in adults 2021: a clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 54: 170\u2013182.","DOI":"10.1016\/j.dld.2021.04.029"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H (2018) The effects of physical exercise on fatty liver disease. Gene Expr 18: 89\u2013101.","DOI":"10.3727\/105221617X15124844266408"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Stavropoulos K, Imprialos K, Pittaras A, Faselis C, Narayan P, et al. (2018) Lifestyle modifications in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Curr Vasc Pharmacol 16: 239\u2013245.","DOI":"10.2174\/1570161115666170621080835"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Han Q, Han X, Wang X, Wang C, Mao M, et al. (2023) Association of accelerometer-measured sedentary behavior patterns with nonalcoholic fatty liver disease among older adults: the MIND-China study. Am J Gastroenterol 118: 569\u2013573.","DOI":"10.14309\/ajg.0000000000002135"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Li P, Yang Q, Wang X, Sun S, Cao W, et al. (2023) Dose-response relationship between physical activity and nonalcoholic fatty liver disease: a prospective cohort study. Chin Med J (Engl) 136: 1494\u20131496.","DOI":"10.1097\/CM9.0000000000002532"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Liu M, Ye Z, Zhang Y, He P, Zhou C, et al. (2024) Accelerometer-derived moderate-to-vigorous physical activity and incident nonalcoholic fatty liver disease. BMC Med 22: 398.","DOI":"10.1186\/s12916-024-03618-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Wang S, Xia BX, Luo T, Wang P (2024) Association between physical activity and diet quality of obese and non-obese MAFLD. Nutr Metab Cardiovasc Dis 34: 75\u201389.","DOI":"10.1016\/j.numecd.2023.07.022"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, et al. (2019) Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 17: 156\u2013163.e152.","DOI":"10.1016\/j.cgh.2018.04.043"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Singh R, Pattisapu A, Emery MS (2020) US physical activity guidelines: current state, impact and future directions. Trends Cardiovasc Med 30: 407\u2013412.","DOI":"10.1016\/j.tcm.2019.10.002"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Seino S, Abe T, Nofuji Y, Hata T, Shinkai S, et al. (2024) Dose-response associations of physical activity and sitting time with all-cause mortality in older Japanese adults. J Epidemiol 34: 23\u201330.","DOI":"10.2188\/jea.JE20220246"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24 Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, et al. (2019) Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156: 1717\u20131730.","DOI":"10.1053\/j.gastro.2019.01.042"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Ciardullo S, Muraca E, Bianconi E, Cannistraci R, Perra S, et al. (2023) Diabetes mellitus is associated with higher serum neurofilament light chain levels in the general US population. J Clin Endocrinol Metab 108: 361\u2013367.","DOI":"10.1210\/clinem\/dgac580"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26 Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, et al. (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77: 1335\u20131347.","DOI":"10.1097\/HEP.0000000000000004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Tabacu L, Swami S, Ledbetter M, Siddiqui MS, Smirnova E (2024) Socioeconomic status and health disparities drive differences in accelerometer-derived physical activity in fatty liver disease and significant fibrosis. PLoS One 19: e0301774.","DOI":"10.1371\/journal.pone.0301774"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Vilar-Gomez E, Nephew LD, Vuppalanchi R, Gawrieh S, Mladenovic A, et al. (2022) High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology 75: 1491\u20131506.","DOI":"10.1002\/hep.32207"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Qiu S, Cai X, Sun Z, Li L, Z\u00fcgel M, et al. (2017) Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. Therap Adv Gastroenterol 10: 701\u2013713.","DOI":"10.1177\/1756283X17725977"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30 Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, et al. (2023) AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77: 1797\u20131835.","DOI":"10.1097\/HEP.0000000000000323"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, et al. (2020) The Asian Pacific Association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 14: 889\u2013919.","DOI":"10.1007\/s12072-020-10094-2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, et al. (2020) World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med 54: 1451\u20131462.","DOI":"10.1136\/bjsports-2020-102955"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Yabut JM, Drucker DJ (2023) Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. Endocr Rev 44: 14\u201332.","DOI":"10.1210\/endrev\/bnac018"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Xie C, Alkhouri N, Elfeki MA (2024) Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: opportunities and challenges. World J Hepatol 16: 731\u2013750.","DOI":"10.4254\/wjh.v16.i5.731"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Zafer M, Tavaglione F, Romero-G\u00f3mez M, Loomba R (2025) Review article: GLP-1 receptor agonists and Glucagon\/GIP\/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD. Aliment Pharmacol Ther 61: 1872\u20131888.","DOI":"10.1111\/apt.70196"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Weinstein AA, Ngo D, de Avila L, Price JK, Golabi P, et al. (2023) Association of physical activity and fine motor performance in individuals with type 2 diabetes mellitus and\/or non-alcoholic fatty liver disease. Ann Med 55: 1345\u20131353.","DOI":"10.1080\/07853890.2023.2193422"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Schneider CV, Zandvakili I, Thaiss CA, Schneider KM (2021) Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort. JHEP Rep 3: 100263.","DOI":"10.1016\/j.jhepr.2021.100263"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Reginato E, Pippi R, Aiello C, Sbroma Tomaro E, Ranucci C, et al. (2019) Effect of short term intensive lifestyle intervention on hepatic steatosis indexes in adults with obesity and\/or type 2 diabetes. J Clin Med 8: 851.","DOI":"10.3390\/jcm8060851"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Abdelbasset WK, Tantawy SA, Kamel DM, Alqahtani BA, Elnegamy TE, et al. (2020) Effects of high-intensity interval and moderate-intensity continuous aerobic exercise on diabetic obese patients with nonalcoholic fatty liver disease: a comparative randomized controlled trial. Medicine (Baltimore) 99: e19471.","DOI":"10.1097\/MD.0000000000019471"},{"key":"40","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1186\/s12889-024-19761-7","volume":"24","author":"X Kong","year":"2024","unstructured":"40 Kong X, Huang R, Geng R, Wu J, Li J, et al. (2024) Associations of ambient air pollution and lifestyle with the risk of NAFLD: a population-based cohort study. BMC Public Health 24: 2354.","journal-title":"BMC Public Health","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2458","issn-type":"print"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Joo JH, Kim HJ, Park EC, Jang SI (2020) Association between sitting time and non-alcoholic fatty live disease in South Korean population: a cross-sectional study. Lipids Health Dis 19: 212.","DOI":"10.1186\/s12944-020-01385-6"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/2\/73_EJ25-0123\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:25:33Z","timestamp":1770434733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/2\/73_EJ25-0123\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0123","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0123"}}